Sponsors

Lead Sponsor

Instil Bio

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histologically documented advanced (metastatic and/or unresectable) cervical cancer, HNSCC, or NSCLC.
•Cohort 1: Participants with cervical cancer whose disease progressed during or after at least 1 prior line of chemotherapy.
•Cohort 2: Participants with HNSCC whose disease progressed during or after chemotherapy that must have included a platinum agent and previous CPI.
•Cohort 3: Participants with NSCLC whose disease progressed during or after 1 prior line of platinum-based chemotherapy and a CPI. Participants with targetable mutations (e.g. EGFR/ALK) are required to have progressed on targeted therapy and platinum-based chemotherapy
•Medically suitable for surgical resection of tumor tissue
•Following tumor resection for TIL harvest, will have, at minimum, 1 remaining measurable lesion as identified by CT or MRI per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
•Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
•Adequate bone marrow and organ function

Exclusion Criteria

•History of another primary malignancy within the previous 3 years
•Neuroendocrine carcinoma, nasopharyngeal carcinoma, squamous cell carcinoma of the lip, or histopathology with neuroendocrine differentiation
•Previously received an allogeneic stem cell transplant or organ allograft
•Previously received TIL or engineered cell therapy (eg, CAR T-cell)
•Significant cardiac disease
•Stroke or transient ischemic attack within 12 months of enrollment
•History of significant central nervous system (CNS) disorder
•Symptomatic and/or untreated CNS metastases
•History of significant autoimmune disease within 2 years prior to enrollment
•Known history of severe, immediate hypersensitivity reaction attributed to cyclophosphamide, fludarabine, IL-2, of CPI

Related studies

RECRUITINGNA

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

NCT07209917 · Cervical Cancer, Human Papillomavirus (HPV) Infection, and more

RECRUITINGPhase 3

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671 · Locally Advanced Cervical Cancer

RECRUITING

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more

RECRUITINGPhase 2

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, and more

RECRUITING

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more

View all related studies →

ITIL-168 in Advanced Solid Tumors

What this study is about

Save this trial guide to your notes